Scientists use denaturing HPLC to identify gene variants in Malaysian familial hypercholesterolemia patients.
Scientists from the Universiti Sains Malaysia (Penang, Malaysia) have studied familial hypercholesterolemia (FH), a genetic disorder caused by defects in the low-density lipoprotein receptor gene, using denaturing high-performance liquid chromatography.
Although FH is a genetic disorder, its phenotypic expression shows great variability in terms of lipid profile, frequency of xanthomas, and onset and severity of cardiovascular disease. In addition, underlying mutations remain largely unknown. The team, led by Alyaa Al-Khateeb of the Human Genome Centre at the Universiti Sains Malaysia, cites these reasons, and the limited analyses of the disorder that have been performed in Malaysia, as reasons to study the molecular spectrum and gene mutations of FH in Malaysian patients.
Low-density lipoprotein receptor (LDLR) gene variants were identified through the use of denaturing high-performance liquid chromatography. In 76% of the analyzed patients with FH, 29 LDLR sequence variants were observed, with eight discovered for the first time in this report.
“These findings support the usefulness of genetic testing, beyond its ability to provide an unequivocal diagnosis of the condition,” writes the team in the March 2011 issue of BMC Medical Genetics.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.